These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2924501)

  • 1. The treatment of essential thrombocythaemia with radioactive phosphorus.
    Wagner S; Waxman J; Sikora K
    Clin Radiol; 1989 Mar; 40(2):190-2. PubMed ID: 2924501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Essential thrombocythaemia and peripheral gangrene.
    Preston FE; Emmanuel IG; Winfield DA; Malia RG
    Br Med J; 1974 Aug; 3(5930):548-52. PubMed ID: 4472103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of different doses of 32P in the treatment of primary thrombocytosis.
    Randi ML; Fabris F; Varotto L; Peverelli P; Girolami A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(6):950-6. PubMed ID: 2419226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of 259 patients with primary proliferative polycythaemia (PPP) and idiopathic thrombocythaemia (IT) treated in a regional nuclear medicine department with phosphorus-32--a 15 year review.
    Balan KK; Critchley M
    Br J Radiol; 1997 Nov; 70(839):1169-73. PubMed ID: 9536909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Essential thrombocythemia: response during first year of therapy with melphalan and radioactive phosphorus: a polycythemia Vera Study Group report.
    Murphy S; Rosenthal DS; Weinfeld A; Briere J; Faguet GB; Knospe WH; Landaw SA; Laszlo J; Pisciotta AV; Tartaglia AP
    Cancer Treat Rep; 1982 Jul; 66(7):1495-500. PubMed ID: 7046930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Essential thrombocythemia. Case reports and clinico-therapeutic considerations].
    Bottaro T; Cordì GC; Gaggero E; Motta A; Venzano C
    Minerva Med; 1990 Mar; 81(3):147-50. PubMed ID: 2320283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases.
    Tennvall J; Brans B
    Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1324-7. PubMed ID: 17396258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anagrelide: a review of its use in the management of essential thrombocythaemia.
    Wagstaff AJ; Keating GM
    Drugs; 2006; 66(1):111-31. PubMed ID: 16398570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haemorrhagic thrombocythaemia; report of two cases treated with radioactive phosphorus.
    FOUNTAIN JR
    Br Med J; 1958 Jul; 2(5089):126-30. PubMed ID: 13560803
    [No Abstract]   [Full Text] [Related]  

  • 10. Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia.
    van Genderen PJ; Michiels JJ
    Presse Med; 1994 Jan; 23(2):73-7. PubMed ID: 8140075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose P32 therapy in essential thrombocythemia.
    Shetty-Alva N; Cheng DW
    Clin Nucl Med; 2006 Dec; 31(12):790-1. PubMed ID: 17117074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probable essential thrombocythemia in a dog.
    Hopper PE; Mandell CP; Turrel JM; Jain NC; Tablin F; Zinkl JG
    J Vet Intern Med; 1989; 3(2):79-85. PubMed ID: 2715960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemorrhagic thrombocythaemia treated with radioactive phosphorus.
    WOODROW JC; COPE S
    Br Med J; 1955 Oct; 2(4947):1069. PubMed ID: 13260666
    [No Abstract]   [Full Text] [Related]  

  • 14. Radiophosphorus (32P) treatment of bone marrow disorders in dogs: 11 cases (1970-1987).
    Smith M; Turrel JM
    J Am Vet Med Assoc; 1989 Jan; 194(1):98-102. PubMed ID: 2914806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance therapy in the myeloproliferative disorders: the current options.
    Giles FJ
    Br J Haematol; 1991 Oct; 79 Suppl 1():92-5. PubMed ID: 1931719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count.
    van Genderen PJ; Budde U; Michiels JJ; van Strik R; van Vliet HH
    Br J Haematol; 1996 Jun; 93(4):962-5. PubMed ID: 8703834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EANM procedure guidelines for 32P therapy.
    EANM
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):BP17-9. PubMed ID: 12723560
    [No Abstract]   [Full Text] [Related]  

  • 18. Pseudohyperkalaemia in thrombocythaemia.
    Wulkan RW; Michiels JJ
    J Clin Chem Clin Biochem; 1990 Jul; 28(7):489-91. PubMed ID: 2230668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies of platelet volume, chemistry and function in patients with essential thrombocythaemia treated with Anagrelide.
    Bellucci S; Legrand C; Boval B; Drouet L; Caen J
    Br J Haematol; 1999 Mar; 104(4):886-92. PubMed ID: 10192455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow cytometry-evaluated platelet CD36 expression, reticulated platelets and platelet microparticles in essential thrombocythaemia and secondary thrombocytosis.
    Moles-Moreau MP; Ternisien C; Tanguy-Schmidt A; Boyer F; Gardembas M; Dib M; Ponthieux A; Guardiola P; Ifrah N; Hunault-Berger M
    Thromb Res; 2010 Nov; 126(5):e394-6. PubMed ID: 20825981
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.